Cite

    Alexander, T., Sarfert, R., Klotsche, J., Kühl, A. A., Rubbert-Roth, A., Lorenz, H., Rech, J., Hoyer, B. F., Cheng, Q., Waka, A., Taddeo, A., Wiesener, M., Schett, G., Burmester, G., Radbruch, A., Hiepe, F., & Voll, R. E. (2015). the proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Annals of the rheumatic diseases, 74(7), 1474–1478. http://access.bl.uk/ark:/81055/vdc_100130159571.0x000052